The Technical Analyst
Kalvista Pharmaceuticals [KALV]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Kalvista Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.61% $11.57
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 488.12 mill |
| EPS: | -3.12 |
| P/E: | -3.71 |
| Earnings Date: | Jul 05, 2024 |
| SharesOutstanding: | 42.19 mill |
| Avg Daily Volume: | 0.824 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.71 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.63x |
| Company: PE -3.71 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.721 (-85.12%) $-9.85 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 10.78 - 12.42 ( +/- 7.04%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-06 | Palleiko Benjamin L | Buy | 250 000 | Restricted Stock Unit |
| 2024-02-20 | Venrock Healthcare Capital Partners Iii, L.p. | Buy | 655 738 | Pre-Funded Warrants (Right to Buy) |
| 2024-02-17 | Feener Edward P. | Buy | 18 788 | Common Stock |
| 2024-02-20 | Feener Edward P. | Sell | 8 397 | Common Stock |
| 2024-02-20 | Feener Edward P. | Sell | 19 591 | Common Stock |
| INSIDER POWER |
|---|
| 65.05 |
| Last 99 transactions |
| Buy: 3 039 025 | Sell: 648 624 |
Forecast:
16:00 - $11.60
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $11.60
Forecast 2: 16:00 - $11.60
Forecast 3: 16:00 - $11.60
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $11.57 (0.61% ) |
| Volume | 0.338 mill |
| Avg. Vol. | 0.824 mill |
| % of Avg. Vol | 41.04 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For KALV
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $14.73 | N/A | Active |
|---|
KALV
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-04-03 06:30:00 - Press Release
Kalvista Pharmaceuticals To Present At 23rd Annual Needham Virtual Healthcare Conference
Cambridge, mass. & salisbury, england--(business wire)--kalvista pharmaceuticals, inc. (nasdaq: kalv), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced its management will participate in a fireside chat at the 23rd annual needham virtual healthcare conference on wednesday, april 10, 2024 at 10:15 a.m. et. a live webcast of the presentation will be available on the company's website a.
2024-04-02 06:30:00 - Press Release
Kalvista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cambridge, mass. & salisbury, england--(business wire)---- $kalv--kalvista pharmaceuticals, inc. (nasdaq: kalv), today announced that the compensation committee of kalvista's board of directors granted nine newly-hired employees inducement options to purchase an aggregate of 65,000 shares of kalvista common stock on april 1, 2024 as inducements material to each employee entering into employment with kalvista. the options were granted in accordance with nasdaq listing rule 5635(c)(4). the options have an.
2024-03-18 06:30:00 - Press Release
Kalvista Pharmaceuticals Presents Real-world Data On Burden Of Treatment And Hae Attack Journey At The 2024 Haei Regional Conference Americas
Cambridge, mass. & salisbury, england--(business wire)---- $kalv--kalvista pharmaceuticals, inc. (nasdaq: kalv), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented multiple analyses of the relationship between the time to attack treatment and the effects delays in treatment have on clinical outcomes of people living with hereditary angioedema (hae) at the 2024 haei regional con.
2024-03-12 06:30:00 - Press Release
Kalvista Pharmaceuticals Awarded Uk Promising Innovative Medicine (pim) Designation For Sebetralstat
Cambridge, mass. & salisbury, england--(business wire)---- $kalv--kalvista pharmaceuticals, inc. (nasdaq: kalv), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the uk medicines and healthcare products regulatory agency (mhra) has awarded the promising innovative medicine (pim) designation for sebetralstat, an investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment.
2024-03-11 06:30:00 - Press Release
Kalvista Pharmaceuticals Reports Third Fiscal Quarter Results And Provides Operational Update
Cambridge, mass. & salisbury, england--(business wire)--kalvista pharmaceuticals, inc. (nasdaq: kalv), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the third fiscal quarter ended january 31, 2024. “this has been an exciting and busy period for kalvista, as we achieved key milestones with the release of our phase 3 konfident.
Latest News
2024-04-03 06:30:00 - Business Wire
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced its management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 10:15 a.m. ET. A live webcast of the presentation will be available on the Company's website a.
2024-03-08 06:30:00 - Business Wire
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2024 HAEi Regional Conference meeting taking place in Panama City, Panama from March 15-17. KalVista is a Silver-level sponsor of the meeting. The presentations are: Relationship Between Tim.
2024-02-16 06:30:00 - Business Wire
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Washington, DC from February 23-26. The following presentations will take place on Saturday,.
2024-02-13 06:43:57 - Reuters
KalVista meets main goals in late-stage trial for skin condition treatment
KalVista Pharmaceuticals said on Tuesday its therapy for a type of skin condition met the main goals in a late-stage trial.
2024-01-03 03:21:42 - Seeking Alpha
KalVista: On Demand Oral Treatment For HAE Signifies Differentiated Advancement
Results from phase 3 KONFIDENT trial, using sebetralstat for on-demand treatment of patients with HAE, expected early 2024. Upon primary endpoint of PGI-C score being met, NDA filing of sebetralstat for HAE expected 1st half of 2024; European and Japan filings expected later in 2024. Oral Factor XIIa inhibitor being advanced for patients with HAE; This could open door to target prophylactic HAE market.
2023-12-07 11:51:23 - InvestorPlace
KALV Stock Earnings: KalVista Pharma Misses EPS for Q2 2024
KalVista Pharma (NASDAQ: KALV ) just reported results for the second quarter of 2024. KalVista Pharma reported earnings per share of -80 cents.
2023-11-14 22:31:22 - InvestorPlace
3 Micro-Cap Stocks That Could Be Moonshots
Amid the valuations of large-cap stocks, notably tech stocks in the Magnificent 7 declining, this has led to this list of micro-cap stocks. Not only are investors expected to rotate into smaller and under-capitalized companies, but these companies also have unique theses that should keep investors interested.
2023-11-07 06:30:00 - Business Wire
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will participate in a fireside chat at the following investor conferences: Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023 at 3:00 p.m. EST Jefferies London Healthcare Conference on Thursday, November 16, 2023 at 9:.
2023-11-02 06:30:00 - Business Wire
KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), taking place in Anaheim, CA from November 9-13. The presentations are: Understanding Why H.
2023-10-01 00:05:36 - Seeking Alpha
KalVista's Sebetralstat: A Pill Worth Swallowing In HAE
KalVista Pharmaceuticals is positioned to disrupt the HAE treatment landscape with its oral therapy, sebetralstat, offering rapid symptom relief and improved patient adherence. Financially, KalVista has a cash runway of about 14 months, but rising G&A costs raise concerns about capital efficiency. Given the statistically significant Phase 2 results, I speculate that the Phase 3 data, expected in Q4 2023, will likely be positive.